Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Recombinant factor VIIa use in acute type A aortic dissection repair : A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection

Zindovic, Igor LU ; Sjögren, Johan LU ; Ahlsson, Anders ; Bjursten, Henrik LU ; Fuglsang, Simon ; Geirsson, Arnar ; Ingemansson, Richard LU ; Hansson, Emma C. ; Mennander, Ari and Olsson, Christian , et al. (2017) In Journal of Thoracic and Cardiovascular Surgery 154(6). p.2-1859
Abstract

Background: Surgery for acute type A aortic dissection (ATAAD) is often complicated by excessive bleeding. Recombinant factor VIIa (rFVIIa) effectively treats refractory bleeding associated with ATAAD surgery; however, adverse effects of rFVIIa in these patients have not been fully assessed. Here we evaluated rFVIIa treatment in ATAAD surgery using the Nordic Consortium for Acute Type A Aortic Dissection (NORCAAD) database. Methods: This was a multicenter, propensity score-matched, retrospective study. Information about rFVIIa use was available for 761 patients, of whom 171 were treated with rFVIIa. We successfully matched 120 patients treated with rFVIIa with 120 controls. Primary endpoints were in-hospital mortality, postoperative... (More)

Background: Surgery for acute type A aortic dissection (ATAAD) is often complicated by excessive bleeding. Recombinant factor VIIa (rFVIIa) effectively treats refractory bleeding associated with ATAAD surgery; however, adverse effects of rFVIIa in these patients have not been fully assessed. Here we evaluated rFVIIa treatment in ATAAD surgery using the Nordic Consortium for Acute Type A Aortic Dissection (NORCAAD) database. Methods: This was a multicenter, propensity score-matched, retrospective study. Information about rFVIIa use was available for 761 patients, of whom 171 were treated with rFVIIa. We successfully matched 120 patients treated with rFVIIa with 120 controls. Primary endpoints were in-hospital mortality, postoperative stroke, and renal replacement therapy (RRT). Survival data were presented using Kaplan-Meier estimates. Results: Compared with controls, patients treated with rFVIIa received more transfusions of packed red blood cells (median, 9.0 U [4.0-17.0 U] vs 5.0 U [2.0-11.0 U]; P = .008), platelets (4.0 U [2.0-8.0 U] vs 2.0 U [1.0-4.4 U]; P <.001), and fresh frozen plasma (8.0 U [4.0-18.0 U] vs 5.5 U [2.0-10.3 U]; P = .01) underwent reexploration for bleeding more often (31.0% vs 16.8%; P = .014); and had greater 24-hour chest tube output (1500 L [835-2500 mL] vs 990 mL [520-1720 mL]). Treatment with rFVIIa was not associated with significantly increased rates of in-hospital mortality (odds ratio [OR], 0.74; 95% confidence interval [CI], 0.34-1.55; P = .487), postoperative stroke (OR, 1.75; 95% CI, 0.82-3.91; P = .163), or RRT (OR, 1.18; 95% CI, 0.48-2.92; P = .839). Conclusions: In this propensity-matched cohort study of patients undergoing ATAAD surgery, treatment with rFVIIa for major bleeding was not associated with a significantly increased risk of stroke, RRT, or mortality.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Aneurysm, Aorta, Dissecting, Hemorrhage
in
Journal of Thoracic and Cardiovascular Surgery
volume
154
issue
6
pages
2 - 1859
publisher
Mosby-Elsevier
external identifiers
  • pmid:28967418
  • wos:000414911900017
  • scopus:85029897638
ISSN
0022-5223
DOI
10.1016/j.jtcvs.2017.08.020
language
English
LU publication?
yes
id
93e2c1c8-4bbc-4619-bb94-bc45531b54bc
date added to LUP
2017-10-10 13:51:09
date last changed
2025-01-07 22:30:25
@article{93e2c1c8-4bbc-4619-bb94-bc45531b54bc,
  abstract     = {{<p>Background: Surgery for acute type A aortic dissection (ATAAD) is often complicated by excessive bleeding. Recombinant factor VIIa (rFVIIa) effectively treats refractory bleeding associated with ATAAD surgery; however, adverse effects of rFVIIa in these patients have not been fully assessed. Here we evaluated rFVIIa treatment in ATAAD surgery using the Nordic Consortium for Acute Type A Aortic Dissection (NORCAAD) database. Methods: This was a multicenter, propensity score-matched, retrospective study. Information about rFVIIa use was available for 761 patients, of whom 171 were treated with rFVIIa. We successfully matched 120 patients treated with rFVIIa with 120 controls. Primary endpoints were in-hospital mortality, postoperative stroke, and renal replacement therapy (RRT). Survival data were presented using Kaplan-Meier estimates. Results: Compared with controls, patients treated with rFVIIa received more transfusions of packed red blood cells (median, 9.0 U [4.0-17.0 U] vs 5.0 U [2.0-11.0 U]; P = .008), platelets (4.0 U [2.0-8.0 U] vs 2.0 U [1.0-4.4 U]; P &lt;.001), and fresh frozen plasma (8.0 U [4.0-18.0 U] vs 5.5 U [2.0-10.3 U]; P = .01) underwent reexploration for bleeding more often (31.0% vs 16.8%; P = .014); and had greater 24-hour chest tube output (1500 L [835-2500 mL] vs 990 mL [520-1720 mL]). Treatment with rFVIIa was not associated with significantly increased rates of in-hospital mortality (odds ratio [OR], 0.74; 95% confidence interval [CI], 0.34-1.55; P = .487), postoperative stroke (OR, 1.75; 95% CI, 0.82-3.91; P = .163), or RRT (OR, 1.18; 95% CI, 0.48-2.92; P = .839). Conclusions: In this propensity-matched cohort study of patients undergoing ATAAD surgery, treatment with rFVIIa for major bleeding was not associated with a significantly increased risk of stroke, RRT, or mortality.</p>}},
  author       = {{Zindovic, Igor and Sjögren, Johan and Ahlsson, Anders and Bjursten, Henrik and Fuglsang, Simon and Geirsson, Arnar and Ingemansson, Richard and Hansson, Emma C. and Mennander, Ari and Olsson, Christian and Pan, Emily and Ullén, Susann and Gudbjartsson, Tomas and Nozohoor, Shahab}},
  issn         = {{0022-5223}},
  keywords     = {{Aneurysm; Aorta; Dissecting; Hemorrhage}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{2--1859}},
  publisher    = {{Mosby-Elsevier}},
  series       = {{Journal of Thoracic and Cardiovascular Surgery}},
  title        = {{Recombinant factor VIIa use in acute type A aortic dissection repair : A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection}},
  url          = {{http://dx.doi.org/10.1016/j.jtcvs.2017.08.020}},
  doi          = {{10.1016/j.jtcvs.2017.08.020}},
  volume       = {{154}},
  year         = {{2017}},
}